Sign In

What's New

Mar 06
40 percent of people in the EU suffer from non-alcoholic steatohepatitis (fatty liver disease), a disease which is becoming increasingly more frequent as a result of diabetes and excess weight in...
Mar 04
Bristol-Myers Squibb Company has announced results from ALLY-2, a Phase III clinical trial evaluating the investigational once-daily regimen of daclatasvir and sofosbuvir for the treatment of...
Mar 03
Yale researchers developed a controlled-release oral therapy that reversed type 2 diabetes and fatty liver disease in rats, according to a study published by Science.
Industry Colloquium

Member Spotlight

Jorge Bezerra, MD, FAASLD

Dr. Jorge Bezerra is Professor of Pediatrics and Director of the Pediatric Liver Care Center and the Digestive Health Center at Cincinnati Children’s Hospital Medical Center.